Exploring Chongqing Pharscin Pharmaceutical Co., Ltd. Investor Profile: Who’s Buying and Why?

Who is behind Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) and what drives their bets? With 39% of shares held by private companies and insiders controlling roughly 35%, the capital structure signals concentrated influence and deep management conviction-anchored by Zhuhai Weilinsi's 39% leading stake and executives Ying Wang and CEO Xiaoying Liu owning ~8.8% and ~8.6% respectively; the market still shows broad interest as public companies and retail investors together account for around 57.53% of shares while institutional names like China Universal, Vanguard and Guotai Junan hold small ETF-linked positions. At an approximate market capitalization of 6.3 billion CNY, Pharscin presents a compelling mix of value and stability: a negative beta of -0.248 that attracts diversification-minded investors, a modest dividend yield of 0.57% for income seekers, a 134.66% jump in net income in 2024 alongside 12.04% revenue growth, and a 7.18% increase in market cap over the past year-facts that set up a nuanced investor profile worth digging into further.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) - Who Invests in Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) and Why?

• Private companies - ~39%: significant block holdings that influence strategic decisions and provide operational stability.
• Insiders - ~35%: high insider ownership signals strong management conviction in future prospects and aligns leadership with shareholder value.
• Public companies + Retail investors - ~57.53%: broad market participation reflecting active trading interest and institutional allocations.

• Why private/strategic investors buy: influence over product strategy, long-term value creation, potential synergies in pharma supply chains.
• Why insiders increase holdings: confidence in R&D pipeline or operational execution, desire to signal strength to the market.
• Why institutions and retail participate: a combination of defensive exposure (negative beta), steady albeit small dividends, and mid-cap growth potential.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) Institutional Ownership and Major Shareholders of Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ)

• Largest shareholder: Zhuhai Weilinsi New Material Development Co., Ltd. - 39.00%.
• Management alignment: Ying Wang (board member) ~8.80%; Xiaoying Liu (CEO) ~8.60% - combined management stake ~17.40%.
• Notable institutional/ETF exposures: China Universal Asset Management, Vanguard, Guotai Junan (combined ~0.25%).

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) Key Investors and Their Impact on Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ)

• Zhuhai Weilinsi - 39.00%: controlling block that drives strategy, board composition and M&A posture.
• Ying Wang - 8.80%: significant shareholder and board member likely prioritizing long-term R&D and pipeline investments.
• Xiaoying Liu - 8.60%: executive-level holder whose stake aligns management incentives with shareholder value and operational execution.
• China Universal Asset Management - 0.10%: institutional investor reflecting sector-focused asset-allocation into Chinese pharma equities.
• Vanguard STAR Funds - 0.09%: modest international passive/active allocation indicating overseas investor confidence in growth potential.
• Guotai Junan Securities - 0.06%: local institutional support signaling recognition of current market position and financial stability.

Ownership concentrations and governance implications (latest reported filings):

• Governance dynamics: with a 39% block, Zhuhai Weilinsi can effectively determine board composition and major corporate actions, making minority holders' influence contingent on alliances with insiders like Ying Wang and Xiaoying Liu.
• Operational alignment: combined insider/management ownership (~17.4%) promotes decision-making that ties executive performance to stockholder outcomes, which typically reduces agency costs.
• Institutional signaling: albeit small percentage holdings, China Universal, Vanguard STAR and Guotai Junan provide monitoring, broaden investor base and can affect analyst coverage and liquidity.
• Capital allocation implications: dominant shareholder control often accelerates or blocks large investments-R&D budgets, manufacturing expansion, licensing deals and potential M&A are filtered through Zhuhai Weilinsi's strategic priorities.

Key metrics for investor monitoring (items investors typically track):

Further corporate context and declared strategic objectives are available here: Mission Statement, Vision, & Core Values (2026) of Chongqing Pharscin Pharmaceutical Co., Ltd.

Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) - Market Impact and Investor Sentiment

• Market capitalization: 6.3 billion CNY - underpins solid investor confidence in company scale and valuation.
• Beta: -0.248 - negative correlation with the market, attracting diversification-seeking investors.
• Dividend yield: 0.57% - modest yield signaling a reinvestment-oriented capital allocation approach.
• Market cap change (1 year): +7.18% - reflects positive sentiment and modest appreciation.
• Revenue growth (2024): +12.04% - strong top-line expansion supporting valuation uplift.
• Net income growth (2024): +134.66% - substantial profitability improvement driving investor reassessment.

• Value and growth-focused domestic funds attracted by accelerating revenue and outsized net income gains.
• Hedge funds and quant strategies seeking negative-beta exposure to reduce portfolio volatility.
• Long-only institutional investors monitoring sustainable cash flows given low dividend payout and reinvestment strategy.
• Retail investors drawn to recent profitability turnaround and visible market-cap appreciation.

• Operational leverage converting revenue growth into outsized net income expansion in 2024.
• Negative beta providing a tactical hedge within diversified equity allocations.
• Market-cap appreciation of 7.18% over 12 months reinforcing momentum-based allocations.
• Management preference for reinvestment over dividends, indicating potential for future organic or M&A-driven growth.